FDA approves spray for plaque psoriasis

The Food and Drug Administration has approved a new drug application for Taro Pharmaceutical Industry’s Topicort (desoximetasone 0.25 percent) topical spray for the treatment of plaque psoriasis.

The corticosteroid is indicated for the treatment of plaque psoriasis in patients ages 18 and older. Annual sales for corticosteroid sprays in the United States total about $100 million, according to a news release.